| Hilary Hanba, MD | |
|
1287 Burns Way, Kalispell, MT 59901 | |
| (406) 752-8120 | |
| (406) 752-8134 |
| Full Name | Hilary Hanba |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1287 Burns Way, Kalispell, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285020263 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 4301107811 (Michigan) | Secondary |
| 208000000X | Pediatrics | 76140 (Montana) | Primary |
| Entity Name | Kalispell Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235333139 PECOS PAC ID: 5294644381 Enrollment ID: O20031122000142 |
News Archive
The Michael J. Fox Foundation for Parkinson's Research announced awards totaling approximately $10.1 million for five new clinical studies and 14 pre-clinical therapeutic development projects. The funding includes $2.5 million to drive four new clinical trials under the Clinical Intervention Awards, one of the Foundation's Edmond J. Safra Core Programs for PD Research.
OraSure Technologies, Inc., a market leader in oral fluid diagnostics, today announced revenues of $75.0 million and $18.8 million for the year and quarter ended December 31, 2010, respectively. This compares to revenues of $77.0 million and $20.9 million for the year and quarter ended December 31, 2009.
The conformance of genetic characteristics is essential for the long-term function after kidney transplantation. This is the central result of a recent study in the top journal "The Lancet" with more than 500 patients after kidney transplantation, conducted by a global consortium led by Rainer Oberbauer and his colleagues Roman Reindl-Schwaighofer and Andreas Heinzel from the Division of Nephrology and Dialysis at MedUni Vienna.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.
A review aimed to determine the potential of siRNA as a potential COVID-19 treatment by reviewing the currently available literature.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hilary Hanba, MD 1287 Burns Way, Kalispell, MT 59901-3109 Ph: (406) 752-8120 | Hilary Hanba, MD 1287 Burns Way, Kalispell, MT 59901 Ph: (406) 752-8120 |
News Archive
The Michael J. Fox Foundation for Parkinson's Research announced awards totaling approximately $10.1 million for five new clinical studies and 14 pre-clinical therapeutic development projects. The funding includes $2.5 million to drive four new clinical trials under the Clinical Intervention Awards, one of the Foundation's Edmond J. Safra Core Programs for PD Research.
OraSure Technologies, Inc., a market leader in oral fluid diagnostics, today announced revenues of $75.0 million and $18.8 million for the year and quarter ended December 31, 2010, respectively. This compares to revenues of $77.0 million and $20.9 million for the year and quarter ended December 31, 2009.
The conformance of genetic characteristics is essential for the long-term function after kidney transplantation. This is the central result of a recent study in the top journal "The Lancet" with more than 500 patients after kidney transplantation, conducted by a global consortium led by Rainer Oberbauer and his colleagues Roman Reindl-Schwaighofer and Andreas Heinzel from the Division of Nephrology and Dialysis at MedUni Vienna.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.
A review aimed to determine the potential of siRNA as a potential COVID-19 treatment by reviewing the currently available literature.
› Verified 2 days ago
Dr. Kenneth V. Akey, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 159 Owl Loop, Kalispell, MT 59901 Phone: 949-633-4008 Fax: 770-683-3019 | |
Margaret Satchell, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-751-5310 | |
Courtney L Stout Paterson, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-751-5310 | |
Kelley Ford Shippey Iii, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 350 Heritage Way Ste 2100, Kalispell, MT 59901 Phone: 406-257-8992 Fax: 406-257-8996 | |
Mrs. Michelle Grace Merchant, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 310 Sunnyview Ln, Kalispell, MT 59901 Phone: 406-758-7036 | |
Lynn Ann Dykstra, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1273 Burns Way, Kalispell, MT 59901 Phone: 406-752-8300 Fax: 406-752-3542 |